GSK2585823(CLDM 1%-BPO 3% gel)
115287
Phase 3 small_molecule completed
Quick answer
GSK2585823(CLDM 1%-BPO 3% gel) for Acne Vulgaris is a Phase 3 program (small_molecule) at GlaxoSmithKline with 1 ClinicalTrials.gov record(s).
Program details
- Company
- GlaxoSmithKline
- Indication
- Acne Vulgaris
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed